Scientific Online Resource System

Heart - Lung (Varna)

Upstream therapy in atrial fibrillation

A. Kisheva, Y. Yotov, A. Angelov, A. Penev

Abstract

atrial fibrillation (aF) is the most common rhythm disorder and a frequent cause for hospitalization and increased mortality and morbidity. the conventional antiarrhythmic therapy has limited options for prevention of aF, so other ways of prevention are being researched. the so-called upstream therapy is being studied for possible beneficial effects and was included in some guidelines of conduct in Europe and worldwide. In this review we indicate the evidence for the effects of different drug classes for primary and secondary prevention of aF. We discuss the action of the inhibitors of the renin-angiotensin system, aldosterone receptors blockers, antilipemic and antioxidant agents and other impact options.


Keywords

atrial fibrillation; prevention; upstream therapy

Full Text


References

Nattel s., B Burstein, d dobrev. atrial Remodeling and atrial Fibrillation: mechanisms and Implications. - Circ arrhythm Electrophysiol, 1, 2008, 62-73.

the task Force for the management of atrial Fibrillation of the European society of Cardiology (EsC). Guidelines for the management of atrial fibrillation. - European Heart Journal, 31, 2010, 2369-242.

Wolf P.a., Rd abbott, WB Kannel. atrial Fibrillation as an Independent Risk Factor for stroke: the Framingham study. - stroke, 22, 1991, 983-988.

Lin H.J., Wolf P.a., Kelly-Hayes m., Beiser a.s., Kase C.s., Benjamin E.J., d`agostino R.B.. stroke severity in atrial fibrillation.the Framingham study. - stroke, 27, 1996, 1760-1764.

Benjamin E. J., P.-s. Chen, d. E. Bild, a. m. mascette,

C. m. albert, a. alonso, H. Calkins, s. J. Connolly, a. B. Curtis, d. darbar, et al. Prevention of atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop. - Circulation, 119, 2009, (4), 606 - 618.

Burstein B, s Nattel. atrial Fibrosis: mechanisms and Clinical Relevance in atrial Fibrillation. -J am Coll Cardiol, 51, 2008, 802-809.

savelieva I, N Kakouros, a Kourliouros, aJ Camm. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European society of Cardiology guidelines. Part I: primary prevention, -Europace, 13, 2011, (3), 308-328.

Camm aJ, Kirchhof P, Lip GyH, savelieva I, Ernst s .atrial fibrillation. In: Camm aJ, Lűsher tF, serruys PW, editors. the EsC textbook of Cardiovascular medicine. Oxford: Blackwell Publishing Ltd; 2009. p. 1069-132.

Goette a, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. -Europace 10, 2008, 238-41.

Cardin s., Li d., thorin-trescases N., Leung t.K., thorin E., Nattel s. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.

-Cardiovasc Res, 60, 2003, 315-2.

Benjamin E.J., Levy d., Vaziri s.m., d'agostino R.B., Belanger a.J., Wolf P.a. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart study. - Jama, 271, 1994, 840-4.

Pedersen O.d., Bagger H., Kober L., torp-Pedersen

C. trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. - Circulation, 100, 1999, 376-80.

Vermes E., tardif J.C., Bourassa m.G., Racine N., Levesque s., White m., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies Of Left Ventricular dysfunction (sOLVd) trials. - Circulation, 103, 2003, 2926-31.

maggioni a.P., Latini R., Carson P.E., singh s.N., Barlera s., Glazer R., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure trial (Val-HeFt). - am Heart J, 149, 2005, 548-57.

ducharme a., swedberg K., Pfeffer m.a., Cohen- solal a., Granger C.B., maggioni a.P., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in mortality and morbidity (CHaRm) program. -am Heart J, 152, 2006, 86-92.

Healey J.s., Baranchuk a., Crystal E., morillo C.a., Garfinkle m., yusuf s., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors

and angiotensin receptor blockers: a meta-analysis. -J am Coll Cardiol, 45, 2005, 1832-9.

anand K., mooss a.N., Hee t.t., mohiuddin s.m. meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. - am Heart J, 152, 2006, 217-22.

Jibrini m.B., molnar J., arora R.R. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. - am J ther, 15, 2008, 36-43.

schneider m.P., Hua t.a., Böhm m., Wachtell K., Kjeldsen s.E., schmieder R.E. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta- analysis. - J am Coll Cardiol, 55, 2010, 2299-307.

de Vos C.B., Pisters R., Nieuwlaat R., Prins m.H., tieleman R.G., Coelen R.J., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. - J am Coll Cardiol, 55, 2010, 725-31.

Wachtell K., Gerdts E., aurigemma G.P., Boman K., dahlöf B., Nieminen m.s., et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the LIFE study. - Blood Pres, 19, 2010, 169-75.

Ruilope L.m., schmieder R.E. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. - am J Hypertens, 2008, 500-8.

Okin P.m., Wachtell K., devereux R.B., Harris K.E., Jern s., Kjeldsen s.E., et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. -Jama, 296, 2006, 1242-8.

schmieder R.E., Kjeldsen s.E., Julius s., mcInnes G.t., Zanchetti a., Hua t.a. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VaLUE trial. - J Hypertens, 26, 2008, 403- 11.

L'allier P.L., ducharme a., Keller P.F., yu H., Guertin m.C., tardif J.C. angiotensin converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. - J am Coll Cardiol, 44, 2004, 159-16.

Hansson L, Lindholm L.H., Niskanen L., Lanke J., Hedner t., Niklason a., et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CaPPP) randomized trial. - Lancet, 353, 1999, 611-6.

Hansson L., Lindholm L.H., Ekbom t., dahlof B., Lanke J., schersten B., et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the swedish trialin Old Patients with Hypertension-2 study. - Lancet, 354, 1999, 1751-6.

salehian O, Healey J, stambler B, alnemer K, almerri K, Grover J, et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. - am Heart J, 154, 2007, 448-53.

yusuf s., teo K., anderson C., Pogue J., dyal L., Copland I., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high- risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. - Lancet, 372, 2008, 1174-83.

White C.m., Kluger J., Lertsburapa K., Faheem O., Coleman C.I. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial FIbrillation suppression trials II and III. - Eur J Cardiothorac surg, 31, 2007, 817-20.

Williams s.G., Connelly d.t., Jackson m., Bennett a., albouaini K., todd d.m. does treatment with aCE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation? - Europace, 7, 2005, 554-9.

madrid a.H., Bueno m.G., Rebollo J.m., marin I., Pena G., Bernal E., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. - Circulation, 106, 2002, 331-6.

Ueng K.C., tsai t.P., yu W.C., tsai C.F., Lin m.C., Chan K.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. - Eur Heart J, 24, 2003, 2090-8.

Van Noord t., Crijns H.J., van den Berg m.P., Van Veldhuisen d.J., Van Gelder I.C.. Pretreatment with aCE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation.

- BmC Cardiovasc disord, 5, 2005, 3.

disertori m., Latini R., Barlera s., Franzosi m.G., staszewsky L., maggioni a.P., et al. Valsartan for prevention of recurrent atrial fibrillation. - N Engl J med, 360, 2009, 1606-17.

yamashita t., Inoue H., Okumura K., Kodama I., aizawa y., atarashi H., et al.; on behalf of the J-RHytHm II Investigators. Randomized trial of angiotensin II- receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHytHm II study). - Europace 2010. Epub ahead of print.

Goette a., Breithardt G., Fetsch t., Hanrath P., Klein H.U., Lehmacher W., et al. angiotensin II antagonist in paroxysmal atrial fibrillation (aNtIPaF) trial: rationale

and study design. - Clin drug Invest, 27, 2007, 697-705.

Bradley a,. maron m.d., Jane a., Leopold m.d., aldosterone Receptor antagonists effective but often forgotten. - Circulation, 121, 2010, 934-939.

Lendeckel U., dobrev d., Goette a. aldosterone- receptor antagonism as a potential therapeutic option for atrial fibrillation. - Br J Pharmacol, 159, 2010, (8), 1581-3.

milliez P., Girerd x., Plouin P.F., Blacher J., safar m.E., mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. - J am Coll Cardiol, 45, 2005, 1243-8.

allan d. struthers; aldosterone: an important mediator of cardiac remodeling in heart failure. - Br J Cardiol, 12, 2005, (3), 211-218.

yang s.s., Han W., Zhou H.y., dong G., Wang B.C., Huo H., et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. - Chin med J (Engl), 121, 2008, 38-42.

Brinkley dm, Chen J. Effect of spironolactone on atrial fibrillation in patients with heart failure. - Heart Rhythm, 7, 2010, s262.

dabrowski R., Borowiec a., smolis-Bak E., Kraska a., Kowalik I., Wozniak J., et al. spironolactone therapy in prevention of atrial fibrillation episodes - final results of open, prospective sPIR-aF study. - Eur Heart J, 31, 2010, 822. abstract.

Karl swedberg, md, Phd; Faiez Zannad, md, Phd; John J.V. mcmurray, md; Eplerenone and atrial Fibrillation in mild systolic Heart Failure, - J am Coll Cardiol, 59, 2012, (18), 1598-1603

savelieva I., Camm a.J. statins and polyunsaturated fatty acids for treatment of atrial fibrillation. - Nat Clin Pract Cardiovasc med, 5, 2008, 30-41.

Hanna I.R., Heeke B., Bush H., Brosius L., King- Hageman d., dudley s.C. Jr., et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. - Heart Rhythm, 3, 2006, 881-6.

dickinson m.G., Hellkamp a.s., Ip J.H., anderson J., Johnson G.W., singh s.N., et al. statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in sCd-HEFt. - Heart Rhythm, 3, 2006, s49.

maggioni a.P., Fabbri G., Lucci d., marchioli R., Franzosi m.G., Latini R., et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GIssI-HF trial. - Eur Heart J, 19, 2009, 2327-36.

Kotlewski a., Liu I.L.a., Khan s.s., shen a.y., Brar

s.s. Prevalence of atrial fibrillation and flutter by different HmG-Coa reductase inhibitors and doses in heart failure.

- J am Coll Cardiol, 47, 2006, 61a.

Wachtell K., Hornestam B., Lehto m., slotwiner d.J., Gerdts E., Olsen m.H., et al. Cardiovascular morbidityand mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. - J am Coll Cardiol, 45, 2005, 705-11.

macfarlane P.W., murray H., sattar N., stott d., Ford I., Buckley B., et al. the incidence and risk factors for new onset atrial fibrillation in the PROsPER study. - Europace 13, 2011, 634-639.

Pellegrini C.N., Vittinghoff E., Lin F., Hulley s.B., marcus Gm. statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERs trial. - Heart, 95, 2009, 704-8.

Bang C.a., Greve m., Olsen H.m., Kober L., Wachtell

K. Effect of statin treatment on atrial fibrillation in patients with asymptomatic aortic stenosis: a sEas substudy. - Eur Heart J, 31, 2010.

Vedre a., Gurm H.s., Froehlich J.B., Kline-Rogers E., montalescot G., Gore J.m., et al. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of acute Coronary Events (GRaCE)). - am J Cardiol, 104, 2009, 1613-7.

danchin N., Fauchier L., marijon E., Barnay C., Furber a., mabo P., et al.; the French registry of acute st-elevation and non-st-elevation myocardial Infarction (Fast-mI) Investigators. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the Fast-mI register. - Heart, 96, 2010, 1809-814.

adabag a.s., mithani s., al aloul B., Collins d., Bertog s., Bloomfield H.E., et al. Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. - am Heart J. 157, 2009, 913-8.

schwartz G.G., Olsson a.G., Chaitman B., Goldberg J., szarek m., sasiela W.J. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the mIRaCL trial. - Circulation, 110, 2004, III-740.

schwartz G.G., Chaitman B.R., Goldberger J.J., messig m. on behalf of the steering Committee of the sPaRCL trial. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the stroke Prevention by aggressive Reduction in Cholesterol Levels (sPaRCL) trial. - am Heart J, 161, 2011, 993-999.

Patti G., Chellom., Candurad., Pasceri V., d'ambrosio a., Covino E., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the aRmyda-3 (atorvastatin for Reduction of myocardial dysrhythmia after cardiac surgery) study. - Circulation, 114, 2006, 1455-61.

Negi s., shukrullah I., Veledar E., Bloom H.L., Jones d.P., dudley s.C. statin therapy for the prevention of atrial fibrillation trial (stoP aF trial). - J Cardiovasc Electrophysiol, 2010. Epub ahead of print.

savelieva I., Kourliouros a., Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. - Naunyn schmiedebergs arch Pharmacol, 381, 2010, 1-13.

mozaffarian d., Psaty B.m., Rimm E.B., Lemaitre R.N., Burke G.L., Lyles m.F., et al. Fish intake and risk of incident atrial fibrillation. - Circulation, 110, 2004, 368-73.

aizer a., Gaziano J.m., manson J.E., Buring J.E., albert C.m. Relationship between fish consumption and the development of atrial fibrillation in men. - Heart Rhythm, 3, 2006, s5.

marik PE, Fromm R. the efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review. - J Crit Care, 24, 2009, 458-463.

Ho K.m., tan J.a. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. - Circulation, 119, 2009, 1853-66.

Baker W.L., White C.m., Kluger J., denowitz a., Konecny C.P., Coleman C.I. Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. - Heart Rhythm, 4, 2007, 461-8.

Busseuil d., shi y.F., mecteau m., Brand G., Gillis m.-a., thorin E., asselin C., Roméo P., Leung t.K., Latour J.-G., des Rosiers C., Bouly m., Rhéaume E., tardif J.-C. Heart Rate Reduction by Ivabradine Reduces diastolic dysfunction and Cardiac Fibrosis. - Cardiology, 177, 2010, 234-242




DOI: http://dx.doi.org/10.14748/hl.v17i3-4.4323

Refbacks

Font Size


|